Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases · 2020 · 2.8K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals

Stanley Xu, Colleen Ross, Marsha A. Raebel et al. · Value in Health · 2009 · 804 citations

Public Health, Biostatistics, Causal Inference +12

Ecological association between a deprivation index and mortality in France over the period 1997 – 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death

Grégoire Rey, Éric Jougla, Anne Fouillet et al. · BMC Public Health · 2009 · 628 citations · Full text

Social Sciences, Demography, Population Health Sciences +17

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen et al. · Annals of the Rheumatic Diseases · 2020 · 221 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17